China Biologic Products (CBPO) 69.12 $CBPO
Your Weekly Review: Growth Stocks Show Signs Of Life
at Investor's Business Daily - Thu Feb 12, 5:12PM CST
The good news for growth investors is that the market is back in a confirmed uptrend. Even better news is that this week's Your Weekly Review screen shows plenty of compelling candidates. Despite nagging distribution days in the S&P 500 and Nasdaq,...
CBPO: 69.12 (+0.42), ZTS: 45.46 (-0.33), SSNC: 63.38 (+1.40), AAP: 150.16 (-1.26), ORLY: 205.55 (-1.02), MIDD: 105.62 (+1.51), SPR: 49.35 (+0.47), MPWR: 50.32 (+0.16), DATA: 99.90 (+1.40)
Regeneron Q4 Sales, 2015 Outlook Upbeat On Eylea
at Investor's Business Daily - Tue Feb 10, 10:01AM CST
Regeneron Pharmaceuticals (REGN) reported weaker-than-expected fourth-quarter earnings Tuesday morning, but the large-cap biotech topped sales views and offered an upbeat outlook for its blockbuster Eylea eye drug, which generates well more than half...
CBPO: 69.12 (+0.42), BIIB: 391.66 (-0.45), INSY: 51.50 (-0.66), PCYC: 163.28 (+0.23), BMRN: 100.76 (+1.98), AMGN: 153.48 (+0.30), SNY: 49.42 (+0.82), REGN: 402.40 (+0.66), CELG: 115.88 (+0.16)
Update: China Biologic Products Adopts Stockholder Plan To Avoid Hostile Takeover
Trevor Lowenthal - at Seeking Alpha - Fri Jan 09, 12:14PM CST
CBPO: 69.12 (+0.42)
Weekly Review Shows Five Industries Gain In December
at Investor's Business Daily - Thu Jan 08, 5:06PM CST
A step back sometimes provides perspective. In this case, a comparison of the current Your Weekly Review list to that of the first week of December shows some revealing changes. Pharmaceutical stocks came under clear pressure during the month, with...
AMBA: 50.71 (-4.46), AKRX: 47.28 (-0.25), AMGN: 153.48 (+0.30), JBLU: 16.83 (+0.09), ACOR: 36.14 (-0.51), MPWR: 50.32 (+0.16), BWLD: 187.27 (+0.30), EAT: 59.16 (-0.18), FRGI: 61.80 (-0.33), LUV: 43.30 (-0.20), CBPO: 69.12 (+0.42), BIDU: 212.13 (+7.11), SWFT: 26.96 (+0.53), KNX: 32.26 (+0.88), ALXN: 182.29 (+6.02), DPZ: 100.00 (-0.56), SAIA: 45.59 (+0.98), AVGO: 110.15 (+0.45), SIMO: 29.08 (-0.39), BABA: 89.05 (+1.95)
China Biologic Adopts Stockholder Rights Plan
PR Newswire - Thu Jan 08, 4:00PM CST
China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"
, a leading fully integrated plasma-based biopharmaceutical company in China, today announced that its board of directors has adopted a stockholder rights plan. Pursuant to the plan, the Company will issue a dividend of one right for each share of its common stock held of record by stockholders as of the close of business on January 20, 2015. China Biologic's board had previously adopted a similar stockholder rights plan on November 19, 2012, which expired on November 20, 2014.
CBPO: 69.12 (+0.42)
Amgen Upgraded to Strong Buy; is it in Your Portfolio? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jan 05, 3:30PM CST
On Jan 3, Zacks Investment Research upgraded Amgen (AMGN) to a Zacks Rank #1 (Strong Buy).
CBPO: 69.12 (+0.42), INCY: 75.94 (+0.28), AMGN: 153.48 (+0.30), AMAG: 41.49 (+0.23)
Zacks Rank #1 Additions for Friday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 02, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday
CBPO: 69.12 (+0.42), DL: 18.44 (+0.60), AIZ: 61.44 (-4.98), ALDW: 17.45 (-0.06), AAL: 48.39 (+0.51)
Biotech Stocks Take A Beating, But Find Support
at Investor's Business Daily - Wed Dec 24, 5:24PM CST
Biotech stocks took a bath in this holiday-shortened week. The catalyst was the announcement by Express Scripts (ESRX), the nation's largest benefits manager, to use AbbVie's (ABBV) hepatitis C drug exclusively. That hurt Gilead Sciences (GILD),...
CBPO: 69.12 (+0.42), ODFL: 76.25 (+0.96), ESRX: 84.90 (+0.40), GILD: 101.90 (+1.10), AMGN: 153.48 (+0.30), ABBV: 58.05 (+1.00), CELG: 115.88 (+0.16)
Update: In An Encouraging Development, China Biologic Products Receives GMP Certification
Trevor Lowenthal - at Seeking Alpha - Wed Dec 24, 1:25PM CST
CBPO: 69.12 (+0.42)
China Biologic passes GMP certification for new coagulation factor facility in China
M2 - Wed Dec 24, 3:31AM CST
Biopharmaceutical company China Biologic Products (NASDAQ:CBPO) reported on Tuesday the receipt of the Good Manufacturing Practices ("GMP" certification from the China Food and Drug Administration (the "CFDA" for its new coagulation factor production facility.
CBPO: 69.12 (+0.42)
China Biologic Receives GMP Certification for New Coagulation Factor Facility
PR Newswire - Tue Dec 23, 7:30AM CST
China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company" , a leading fully integrated plasma-based biopharmaceutical company in China, today announced that its majority-owned subsidiary, Shandong Taibang Biological Products Co. Ltd., has received Good Manufacturing Practices ("GMP" certification from the China Food and Drug Administration (the "CFDA" for its new coagulation factor production facility. As previously disclosed in the Company's public filings, the CFDA inspected this new facility for GMP compliance in June 2014.
CBPO: 69.12 (+0.42)
Fibrinogen Deficiency (Factor I Deficiency) - Pipeline Review, H2 2014
M2 - Fri Dec 19, 5:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/k57j8c/fibrinogen) has announced the addition of the "Fibrinogen Deficiency (Factor I Deficiency) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Fibrinogen Deficiency (Factor I Deficiency), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fibrinogen Deficiency (Factor I Deficiency) and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Fibrinogen Deficiency (Factor I Deficiency) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Fibrinogen Deficiency (Factor I Deficiency) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Biotest AG - China Biologic Products, Inc. - LFB S.A. For more information visit http://www.researchandmarkets.com/research/k57j8c/fibrinogen
CBPO: 69.12 (+0.42)
Newly Profitable Medivation Riding High On Drug Sales
at Investor's Business Daily - Fri Nov 28, 4:20PM CST
Biopharmaceutical company Medivation (MDVN) recently turned profitable in a big way. The company -- a new entrant to the IBD Stock Spotlight screen -- focuses on developing therapies to treat serious illnesses for which few treatment options exist....
CBPO: 69.12 (+0.42), MDVN: 104.71 (+0.67), ALXN: 182.29 (+6.02), CELG: 115.88 (+0.16)
China Blood Product Industry Outlook 2017
M2 - Wed Nov 26, 4:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/kqzgrl/china_blood) has announced the addition of the "China Blood Product Industry Outlook 2017" report to their offering. Plasma resource reserves and control are crucial to the development of blood products industry. Although the closure of 16 plasma collection stations in Guizhou in 2011 didn't cause major disruption to domestic blood products market, the total plasma volume in China blood products industry reduced by 2.8% year on year and total lot release volume declined by 7% from a year earlier in 2013, due to stock consumption, insufficient utilization of new plasma stations and production break of some companies (e.g. Guizhou Taibang Biological Products Co., Ltd and Guangdong Wellen Biological Pharmaceutical Co., Ltd. on account of upgrading and reconstruction, Shanghai RAAS Blood Products Co., Ltd. affected by floods). However, some niche varieties of blood products, such as scarce human coagulation factor VIII, maintained higher growth in lot release volume. In 2013, the human coagulation factor VIII produced by Shandong Taibang and CNBG Shanghai Institute of Biological Products were approved for release and came into the market, making the lot release volume of the product during the same period amount to 526,000 bottles, soaring by 44.5% on year-on-year basis. In addition, as the Ministry of Health stipulates that the blood products production units with registered varieties of blood products less than 6, and the blood products production units, which undertake national planned immunization task, with registered varieties of blood products less than 5, shall not apply to set up new plasmapheresis centers. Therefore, some superior blood products companies are improving their competitiveness by acquiring small ones which have single product mix but plasma stations. In June 2013, Jiangxi Boya Bio-pharmaceutical Co., Ltd. acquired 32% stake in Zhejiang Haikang Biological Products Co., Ltd., which had two plasma stations and held 41.98% stake in Xinjiang Deyuan Bioengineering Co., Ltd., which possessed 6 plasma stations. In March 2013, Shanghai RAAS set about purchasing Zhengzhou Banghe Pharmaceutical (now known as Zhengzhou RAAS) with RMB1.8 billion, with capital settlement completed in January 2014. Key Topics Covered: 1. Overview of Blood Product Industry 2. Overview of China Blood Product Industry 3. Blood Product Market Segments in China 4. Major Chinese Manufacturers 5. Summary and Forecast Companies Mentioned - Beijing Tiantan Biological Products Co., Ltd. - Chengdu Rongsheng Pharmaceutical Co., Ltd. - China Biologic Products Inc. - Green Cross - Guangdong Shuanglin Bio-Pharmacy Co., Ltd. - Guizhou Taibang Biological Products Co., Ltd. - Hebei Da'an Pharmaceutical Co., Ltd. - Hualan Biological Engineering Inc. - Humanwell Healthcare Group Co., Ltd. - Jiangxi Boya Bio-Pharmaceutical Co., Ltd. - Shandong Taibang Biological Products Co., Ltd. - Shanghai Institute of Biological Products Co., Ltd. - Shanghai RAAS Blood Products Co., Ltd. - Shanxi Kangbao Biological Product Co., Ltd. - Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. - Walvax Biotechnology Co, Ltd. - Wuhan Zhongyuan Ruide Biological Product Co., Ltd. - Xi'an Huitian Blood Products Co., Ltd. - Zhenxing Biopharmaceutical and Chemical Co., Ltd. For more information visit http://www.researchandmarkets.com/research/kq...hina_blood
CBPO: 69.12 (+0.42)
Nasdaq stocks posting largest percentage decreases
AP - Tue Nov 11, 12:52PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
CLUB: 6.94 (+0.10), CBPO: 69.12 (+0.42), DSCI: 8.90 (+0.02), HYGS: 14.25 (-0.28), MYGN: 34.03 (+0.40), MCEP: 6.29 (+0.12), HIIQ: 8.03 (+0.16), HYG.TO: 17.60 (-0.51), SLTC: 4.84 (+0.02), ASEI: 56.82 (+0.30), MTEX: 23.89 (+0.69), PLNR: 6.63 (-0.07)
China Biologic Products (CBPO) Crumbles: Stock Falls by 6.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 7:39AM CST
Make sure to keep a close watch on China Biologic Products in the near future, and especially on earnings estimates following the recent slump.
CBPO: 69.12 (+0.42)
China Biologic Products' (CBPO) CEO David Gao on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 11:39PM CST
CBPO: 69.12 (+0.42)
Update: China Biologic Products Q3 Earnings Beat
Trevor Lowenthal - at Seeking Alpha - Thu Nov 06, 4:50AM CST
CBPO: 69.12 (+0.42)
China Biologic Products beats by $0.17, beats on revenue
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 5:27PM CST
CBPO: 69.12 (+0.42)
China Biologic Reports Financial Results for the Third Quarter and First Nine Months of 2014
PR Newswire - Wed Nov 05, 4:00PM CST
China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company" , a leading fully integrated plasma-based biopharmaceutical company in China, today announced its unaudited financial results for the third quarter of 2014.
CBPO: 69.12 (+0.42)
Your Weekly Review: Growth Stocks Show Signs Of Life
at Investor's Business Daily - Thu Feb 12, 5:12PM CST
The good news for growth investors is that the market is back in a confirmed uptrend. Even better news is that this week's Your Weekly Review screen shows plenty of compelling candidates. Despite nagging distribution days in the S&P 500 and Nasdaq,...
CBPO: 69.12 (+0.42), ZTS: 45.46 (-0.33), SSNC: 63.38 (+1.40), AAP: 150.16 (-1.26), ORLY: 205.55 (-1.02), MIDD: 105.62 (+1.51), SPR: 49.35 (+0.47), MPWR: 50.32 (+0.16), DATA: 99.90 (+1.40)
Regeneron Q4 Sales, 2015 Outlook Upbeat On Eylea
at Investor's Business Daily - Tue Feb 10, 10:01AM CST
Regeneron Pharmaceuticals (REGN) reported weaker-than-expected fourth-quarter earnings Tuesday morning, but the large-cap biotech topped sales views and offered an upbeat outlook for its blockbuster Eylea eye drug, which generates well more than half...
CBPO: 69.12 (+0.42), BIIB: 391.66 (-0.45), INSY: 51.50 (-0.66), PCYC: 163.28 (+0.23), BMRN: 100.76 (+1.98), AMGN: 153.48 (+0.30), SNY: 49.42 (+0.82), REGN: 402.40 (+0.66), CELG: 115.88 (+0.16)
Update: China Biologic Products Adopts Stockholder Plan To Avoid Hostile Takeover
Trevor Lowenthal - at Seeking Alpha - Fri Jan 09, 12:14PM CST
CBPO: 69.12 (+0.42)
Weekly Review Shows Five Industries Gain In December
at Investor's Business Daily - Thu Jan 08, 5:06PM CST
A step back sometimes provides perspective. In this case, a comparison of the current Your Weekly Review list to that of the first week of December shows some revealing changes. Pharmaceutical stocks came under clear pressure during the month, with...
AMBA: 50.71 (-4.46), AKRX: 47.28 (-0.25), AMGN: 153.48 (+0.30), JBLU: 16.83 (+0.09), ACOR: 36.14 (-0.51), MPWR: 50.32 (+0.16), BWLD: 187.27 (+0.30), EAT: 59.16 (-0.18), FRGI: 61.80 (-0.33), LUV: 43.30 (-0.20), CBPO: 69.12 (+0.42), BIDU: 212.13 (+7.11), SWFT: 26.96 (+0.53), KNX: 32.26 (+0.88), ALXN: 182.29 (+6.02), DPZ: 100.00 (-0.56), SAIA: 45.59 (+0.98), AVGO: 110.15 (+0.45), SIMO: 29.08 (-0.39), BABA: 89.05 (+1.95)
China Biologic Adopts Stockholder Rights Plan
PR Newswire - Thu Jan 08, 4:00PM CST
China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"
, a leading fully integrated plasma-based biopharmaceutical company in China, today announced that its board of directors has adopted a stockholder rights plan. Pursuant to the plan, the Company will issue a dividend of one right for each share of its common stock held of record by stockholders as of the close of business on January 20, 2015. China Biologic's board had previously adopted a similar stockholder rights plan on November 19, 2012, which expired on November 20, 2014. CBPO: 69.12 (+0.42)
Amgen Upgraded to Strong Buy; is it in Your Portfolio? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jan 05, 3:30PM CST
On Jan 3, Zacks Investment Research upgraded Amgen (AMGN) to a Zacks Rank #1 (Strong Buy).
CBPO: 69.12 (+0.42), INCY: 75.94 (+0.28), AMGN: 153.48 (+0.30), AMAG: 41.49 (+0.23)
Zacks Rank #1 Additions for Friday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 02, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday
CBPO: 69.12 (+0.42), DL: 18.44 (+0.60), AIZ: 61.44 (-4.98), ALDW: 17.45 (-0.06), AAL: 48.39 (+0.51)
Biotech Stocks Take A Beating, But Find Support
at Investor's Business Daily - Wed Dec 24, 5:24PM CST
Biotech stocks took a bath in this holiday-shortened week. The catalyst was the announcement by Express Scripts (ESRX), the nation's largest benefits manager, to use AbbVie's (ABBV) hepatitis C drug exclusively. That hurt Gilead Sciences (GILD),...
CBPO: 69.12 (+0.42), ODFL: 76.25 (+0.96), ESRX: 84.90 (+0.40), GILD: 101.90 (+1.10), AMGN: 153.48 (+0.30), ABBV: 58.05 (+1.00), CELG: 115.88 (+0.16)
Update: In An Encouraging Development, China Biologic Products Receives GMP Certification
Trevor Lowenthal - at Seeking Alpha - Wed Dec 24, 1:25PM CST
CBPO: 69.12 (+0.42)
China Biologic passes GMP certification for new coagulation factor facility in China
M2 - Wed Dec 24, 3:31AM CST
Biopharmaceutical company China Biologic Products (NASDAQ:CBPO) reported on Tuesday the receipt of the Good Manufacturing Practices ("GMP"
certification from the China Food and Drug Administration (the "CFDA" for its new coagulation factor production facility. CBPO: 69.12 (+0.42)
China Biologic Receives GMP Certification for New Coagulation Factor Facility
PR Newswire - Tue Dec 23, 7:30AM CST
China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"
, a leading fully integrated plasma-based biopharmaceutical company in China, today announced that its majority-owned subsidiary, Shandong Taibang Biological Products Co. Ltd., has received Good Manufacturing Practices ("GMP" certification from the China Food and Drug Administration (the "CFDA" for its new coagulation factor production facility. As previously disclosed in the Company's public filings, the CFDA inspected this new facility for GMP compliance in June 2014. CBPO: 69.12 (+0.42)
Fibrinogen Deficiency (Factor I Deficiency) - Pipeline Review, H2 2014
M2 - Fri Dec 19, 5:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/k57j8c/fibrinogen) has announced the addition of the "Fibrinogen Deficiency (Factor I Deficiency) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Fibrinogen Deficiency (Factor I Deficiency), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fibrinogen Deficiency (Factor I Deficiency) and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Fibrinogen Deficiency (Factor I Deficiency) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Fibrinogen Deficiency (Factor I Deficiency) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Biotest AG - China Biologic Products, Inc. - LFB S.A. For more information visit http://www.researchandmarkets.com/research/k57j8c/fibrinogen
CBPO: 69.12 (+0.42)
Newly Profitable Medivation Riding High On Drug Sales
at Investor's Business Daily - Fri Nov 28, 4:20PM CST
Biopharmaceutical company Medivation (MDVN) recently turned profitable in a big way. The company -- a new entrant to the IBD Stock Spotlight screen -- focuses on developing therapies to treat serious illnesses for which few treatment options exist....
CBPO: 69.12 (+0.42), MDVN: 104.71 (+0.67), ALXN: 182.29 (+6.02), CELG: 115.88 (+0.16)
China Blood Product Industry Outlook 2017
M2 - Wed Nov 26, 4:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/kqzgrl/china_blood) has announced the addition of the "China Blood Product Industry Outlook 2017" report to their offering. Plasma resource reserves and control are crucial to the development of blood products industry. Although the closure of 16 plasma collection stations in Guizhou in 2011 didn't cause major disruption to domestic blood products market, the total plasma volume in China blood products industry reduced by 2.8% year on year and total lot release volume declined by 7% from a year earlier in 2013, due to stock consumption, insufficient utilization of new plasma stations and production break of some companies (e.g. Guizhou Taibang Biological Products Co., Ltd and Guangdong Wellen Biological Pharmaceutical Co., Ltd. on account of upgrading and reconstruction, Shanghai RAAS Blood Products Co., Ltd. affected by floods). However, some niche varieties of blood products, such as scarce human coagulation factor VIII, maintained higher growth in lot release volume. In 2013, the human coagulation factor VIII produced by Shandong Taibang and CNBG Shanghai Institute of Biological Products were approved for release and came into the market, making the lot release volume of the product during the same period amount to 526,000 bottles, soaring by 44.5% on year-on-year basis. In addition, as the Ministry of Health stipulates that the blood products production units with registered varieties of blood products less than 6, and the blood products production units, which undertake national planned immunization task, with registered varieties of blood products less than 5, shall not apply to set up new plasmapheresis centers. Therefore, some superior blood products companies are improving their competitiveness by acquiring small ones which have single product mix but plasma stations. In June 2013, Jiangxi Boya Bio-pharmaceutical Co., Ltd. acquired 32% stake in Zhejiang Haikang Biological Products Co., Ltd., which had two plasma stations and held 41.98% stake in Xinjiang Deyuan Bioengineering Co., Ltd., which possessed 6 plasma stations. In March 2013, Shanghai RAAS set about purchasing Zhengzhou Banghe Pharmaceutical (now known as Zhengzhou RAAS) with RMB1.8 billion, with capital settlement completed in January 2014. Key Topics Covered: 1. Overview of Blood Product Industry 2. Overview of China Blood Product Industry 3. Blood Product Market Segments in China 4. Major Chinese Manufacturers 5. Summary and Forecast Companies Mentioned - Beijing Tiantan Biological Products Co., Ltd. - Chengdu Rongsheng Pharmaceutical Co., Ltd. - China Biologic Products Inc. - Green Cross - Guangdong Shuanglin Bio-Pharmacy Co., Ltd. - Guizhou Taibang Biological Products Co., Ltd. - Hebei Da'an Pharmaceutical Co., Ltd. - Hualan Biological Engineering Inc. - Humanwell Healthcare Group Co., Ltd. - Jiangxi Boya Bio-Pharmaceutical Co., Ltd. - Shandong Taibang Biological Products Co., Ltd. - Shanghai Institute of Biological Products Co., Ltd. - Shanghai RAAS Blood Products Co., Ltd. - Shanxi Kangbao Biological Product Co., Ltd. - Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. - Walvax Biotechnology Co, Ltd. - Wuhan Zhongyuan Ruide Biological Product Co., Ltd. - Xi'an Huitian Blood Products Co., Ltd. - Zhenxing Biopharmaceutical and Chemical Co., Ltd. For more information visit http://www.researchandmarkets.com/research/kq...hina_blood
CBPO: 69.12 (+0.42)
Nasdaq stocks posting largest percentage decreases
AP - Tue Nov 11, 12:52PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
CLUB: 6.94 (+0.10), CBPO: 69.12 (+0.42), DSCI: 8.90 (+0.02), HYGS: 14.25 (-0.28), MYGN: 34.03 (+0.40), MCEP: 6.29 (+0.12), HIIQ: 8.03 (+0.16), HYG.TO: 17.60 (-0.51), SLTC: 4.84 (+0.02), ASEI: 56.82 (+0.30), MTEX: 23.89 (+0.69), PLNR: 6.63 (-0.07)
China Biologic Products (CBPO) Crumbles: Stock Falls by 6.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 7:39AM CST
Make sure to keep a close watch on China Biologic Products in the near future, and especially on earnings estimates following the recent slump.
CBPO: 69.12 (+0.42)
China Biologic Products' (CBPO) CEO David Gao on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 11:39PM CST
CBPO: 69.12 (+0.42)
Update: China Biologic Products Q3 Earnings Beat
Trevor Lowenthal - at Seeking Alpha - Thu Nov 06, 4:50AM CST
CBPO: 69.12 (+0.42)
China Biologic Products beats by $0.17, beats on revenue
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 5:27PM CST
CBPO: 69.12 (+0.42)
China Biologic Reports Financial Results for the Third Quarter and First Nine Months of 2014
PR Newswire - Wed Nov 05, 4:00PM CST
China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"
, a leading fully integrated plasma-based biopharmaceutical company in China, today announced its unaudited financial results for the third quarter of 2014. CBPO: 69.12 (+0.42)
